Fosun to Start US Trial of COVID-19 Antibody Treatment
October 09, 2020 at 09:36 AM EDT
Fosun Pharma was granted US FDA approval to begin clinical tests of an investigational COVID-19 antibody treatment, HLX70. The trial will be conducted by Hengenix Biotech, the California arm of Fosun's biologics subsidiary, Henlius. Hengenix co-developed the molecule with Sanyou Biopharma, a CRO, and Shanghai ZJ Bio-Tech. It is aimed at treating the acute respiratory distress syndrome and multiple organ failure that is associated with COVID-19. More details.... Stock Symbols: (SHA: 600196; HK: 02196) (HK: 2696) Share this with colleagues: // //
